The prognostic value of the topographic distribution of uPAR expression in invasive breast carcinomas

Cancer Letters

Volumn 246, Issue 1-2, 2007, Pages 262-267

  Giannopoulou, I ^a   Mylona, E ^a   Kapranou, A ^a   Mavrommatis, J ^a   Markaki, S ^b   Zoumbouli, Ch ^b   Keramopoulos, A ^b   Nakopoulou, L ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Breast cancer; Immunohistochemistry; Survival; uPAR

Indexed keywords

PARAFFIN; UROKINASE;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNODETECTION; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; KAPLAN MEIER METHOD; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN LOCALIZATION; STROMA CELL; TOPOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CYTOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, CELL SURFACE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 33845602208     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.03.003     Document Type: Article

References (27)

1. Andreasen P.A., Kjoeller L., Christensen L., and Duffy M.J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer 72 (1997) 1-22
2. Schmitt M., Harbeck N., Thomssen C., Wilhelm O., Magdolem V., Rheuning U., et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb. Haemost. 78 (1987) 285-296
3. Choong P.-F.M., and Nadesapillai A.-P.W. Urokinase plasminogen activator system-a multifunction role in tumor progression and metastsais. Cl. Orthop. Rel. Res. 415S (2003) S46-S58
4. de Bock C.E., and Wang Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med. Res. Rev. 24 (2004) 13-39
5. Blasi F., and Carmeliet P. UPAR: a versatile signaling orchestrator. Nat. Rev. Mol. Cell Biol. 3 (2002) 932-943
6. Duggan C., Maguire T., McDermott E., O'Higgins N., Fennelly J.J., and Duffy M.J. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int. J. Cancer 61 (1995) 597-600
7. Grondahl-Hansen J., Peters H.A., van Putten W.L., Look M.P., Rappot H., Ronne E., et al. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin. Cancer Res. 1 (1995) 1079-1087
8. Bouchet C., Hacene K., Martin P.M., Becette V., Tubiana-Hulin M., Lasry S., et al. Dissemination risk index based on plasminogen activator system components in primary breast cancer. J. Clin. Oncol. 17 (1999) 3048-3057
9. de Witte J.H., Foekens J.A., Brunner N., Heuvel J.J., van Tienoven T., Look M.P., et al. Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours. Br. J. Cancer 85 (2001) 85-92
10. Pacheco M.M., Nishimoto I.N., Mourao Neto M., Mantovani E.B., and Brentani M.M. Prognostic significance of the combined expression of matrix metalloproteinase-9, urokinase type plasminogen activator and it receptor in breast cancer as measured by Northern blot analysis. Int. J. Biol. Markers 16 (2001) 62-68
11. Foekens J.A., Peters H.A., Look M.P., Portengen H., Schmitt M., Kramer M.D., et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. 60 (2000) 636-643
12. Tavasseo'li F.A., and Devillee P. Pathology and genetics. Tumours of the breast and female genital organs. IARC WHO Classification of Tumours (2003) 10-111
13. Elston C.W. Grading of invasive carcinoma of the breast. In: Page D.L., and Anderson T.J. (Eds). Diagnostic Histopathology of the Breast (1987), Churchill Livingstone, Edinburgh 300-311
14. Union international centre cancer. TNM classification of international union against cancer. In: Hermanek P., and Sabin L.H. (Eds). TNM Atlas. fourth ed (1992), Springer, Berlin [3rd revision]
15. McClelland R.A., Wilson D., Leake R., Finlay P., and Nicholson R.I. A multicentre study into the reliability of steroid receptor immunocytochemical assay quantification. Eur. J. Cancer 27 (1991) 711-716
16. Bianchi E., Cohen R.L., Thor A.T., Todd R.F., Mizukami I.F., Lawrence D.A., et al. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res. 54 (1994) 861-866
17. Costantini V., Sidoni A., Deveglia R., Cazzato O.A., Bellezza G., Ferri I., et al. Combined overexpression of urokinase, urokinase receptor and plasminogen activator inhibitor-1 is associated with breast cancer progression: An immunohistochemical comparison of normal, benign and malignant breast tissues. Cancer 77 (1996) 1079-1088
18. Fisher J.L., Field C.L., Zhou H., Harris T.L., Henderson M.A., and Choong P.F. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases-A comparison of normal breast issue, non-invasive and invasive carcinoma and osseous metastases. Breast Cancer Res. Treat. 61 (2000) 1-12
19. Kim S.J., Shiba E., Taguchi T., Watanabe T., Tanji Y., Kimoto Y., et al. Urokinase type plasminogen activator receptor is a novel prognostic factor in breast cancer. Anticancer Res. 17 (1997) 1373-1378
20. Kennedy S., Duffy M.J., Duggan C., Barnes C., Rafferty R., and Kramer M.D. Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry. Br. J. Cancer 77 (1998) 1638-1641
21. Hildenbrand R., Glienke W., Magdolen V., Graeff H., Stutte H.J., and Schmitt M. Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry. Histochem. Cell Biol. 110 (1998) 27-32
22. Dublin E., Hanby A., Patel N.K., Liebman R., and Barnes D. Immunohistochemical expression of uPA, uPAR and PAI-1 in breast carcinoma: Fibroblastic expression has strong associations with tumor pathology. Am. J. Pathol. 157 (2000) 1219-1227
23. Romer J., Pyke C., Lund L.R., Eriksen J., Kristensen P., Ronne E., et al. Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion. Int. J. Cancer 57 (1994) 553-560
24. Hemsen A., Riethdorf L., Brunner N., Berger J., Ebel S., Thomssen C., et al. Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells. Int. J. Cancer 107 (2003) 903-909
25. Pierga J.Y., Bonneton C., Magdelenat H., Vincent-Salomon A., Nos C., Boudou E., et al. Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients. Int. J. Cancer 114 (2005) 291-298
26. Schneider J., Lucas R., Sanchez J., Tejerina A., and Ruibal A. Cellular accumulation of UPA-PAI-1 and UPA-PAI-2 complexes in early (pT1) breast cancer: a new link in the uPA-UPAr-PAI chain. In Vivo 14 (2000) 507-511
27. Shekhar M., Pauley R., and Heppner G. Extracellular matrix-stromal cell contribution to neoplastic phenotype of epithelial cells in the breast. Breast Cancer Res. 5 (2003) 130-135